An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
Clinical trial NCT06910137 · AVAILABLE
Trial details
- NCT number
- NCT06910137
- Sponsor
- Incyte Corporation
- Status
- AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.